tradingkey.logo

Elutia Inc

ELUT
View Detailed Chart
0.960USD
+0.040+4.35%
Close 11/05, 16:00ETQuotes delayed by 15 min
40.70MMarket Cap
LossP/E TTM

Elutia Inc

0.960
+0.040+4.35%
Intraday
1m
30m
1h
D
W
M
D

Today

+4.35%

5 Days

+6.31%

1 Month

+9.09%

6 Months

-49.47%

Year to Date

-74.33%

1 Year

-74.93%

View Detailed Chart

TradingKey Stock Score of Elutia Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Elutia Inc's Score

Industry at a Glance

Industry Ranking
85 / 159
Overall Ranking
221 / 4616
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
4.000
Target Price
+334.78%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Elutia Inc Highlights

StrengthsRisks
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
Growing
The company is in a growing phase, with the latest annual income totaling USD 24.38M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 24.38M.
Undervalued
The company’s latest PE is -3.19, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 26.67M shares, decreasing 0.23% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.18M shares of this stock.

Elutia Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Elutia Inc Info

Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
Ticker SymbolELUT
CompanyElutia Inc
CEODr. C. Randal (Randal) Mills, Ph.D.
Websitehttps://elutia.com/
KeyAI